Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Anaadriana Zakarija, MD, Thanh Ha Luu, Hau C. Kwaan, MD, PhD, June McKoy, MD, JD, MPH, Ivy Weiss, BS, Paul Yarnold, Nicholas Bandarenko, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 892.

https://doi.org/10.1182/blood.V114.22.892.892

Published: 2009

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

Journal Articles

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Charles L. Bennett, MD, PhD, MPP, Thanh Ha Luu, BA, Anaadriana Zakarija, MD, Hau C. Kwaan, MD, PhD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, John F. Cursio, MS, June M. McKoy, MD, JD, MPH, Charlie Buffie, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD, Ravindra Sarode, MD, X. Long Zheng, MD, PhD, Thomas J. Raife, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Gail A. Rock, MD, PhD

Blood (2007) 110 (11): 2088.

https://doi.org/10.1182/blood.V110.11.2088.2088

Published: 2007

Journal Articles

Preliminary Results from the Surveillance, Epidemiology & Risk Factors for TTP (SERF-TTP) Group: A Prospective Case-Control Study of Idiopathic TTP.

Anaadriana Zakarija, MD, H.C. Kwaan, MD PhD, Nicholas Bandarenko, MD, Dilip Pandey, MD PhD, Amul Tevar, MS, John Cursio, MS, Charles Buffie, BA, Thomas Ortel, MD PhD, Jeffrey Winters, MD, Joseph Kiss, MD, Ravindra Sarode, MD, Charles Bennett, MD PhD

Blood (2006) 108 (11): 1063.

https://doi.org/10.1182/blood.V108.11.1063.1063

Published: 2006

Journal Articles

ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).

H.C. Kwaan, MD, PhD, June M. McKoy, MD, MPH, JD, Kathryn R. McCaffrey, BA, Paul R. Yarold, PhD, Benjamin Kim, MD, Anaadriana Zakarija, MD, Nicholas Bandarenko, MD, Dilip K. Pandey, MD, PhD, James N. George, MD, X. Long Zheng, MD, PhD, Kenneth R. Carson, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2005) 106 (11): 60.

https://doi.org/10.1182/blood.V106.11.60.60

Published: 2005

Journal Articles

Incident TTP: Plasmapheresis Therapy-Related Complications Are Common.

Anaadriana Zakarija, MD, Kathryn R. McCaffrey, BA, Nicholas Bandarenko, MD, Dilip Pandey, MD, PhD, John Cursio, MS, Amul Tevar, MPH, Hau Kwaan, MD, PhD, Paul R. Yarnold, PhD, Maddie Burton, Charles L. Bennett, MD, PhD, MPP

Blood (2005) 106 (11): 1254.

https://doi.org/10.1182/blood.V106.11.1254.1254

Published: 2005

Journal Articles

Preliminary Findings from the Prospective Multicenter Surveillance, Epidemiology and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Anaadriana Zakarija, MD, Nicholas Bandarenko, MD, Dilip K. Pandey, Hau Kwaan, MD, PhD, Kathryn McCaffrey, BA, Denise Finley, BA, Ken Carson, MD, Paul Yarnold, PhD, Charles L. Bennett, MD, PhD

Blood (2004) 104 (11): 855.

https://doi.org/10.1182/blood.V104.11.855.855

Published: 2004

Journal Articles

Are There Two Distinct Mechanistic Pathways That Explain the Varying Clinical Presentations, Laboratory Findings, and Outcomes of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP)?.

Benjamin Kim, MD, Kenneth R. Carson, MD, Kathryn McCaffrey, BA, Denise Finley, Anaadriana Zakarija, MD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, Dennis W. Raisch, PhD, Hau C. Kwaan, MD, PhD, Paul R. Yarnold, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2004) 104 (11): 860.

https://doi.org/10.1182/blood.V104.11.860.860

Published: 2004

NARROW

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Preliminary Results from the Surveillance, Epidemiology & Risk Factors for TTP (SERF-TTP) Group: A Prospective Case-Control Study of Idiopathic TTP.

ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).

Incident TTP: Plasmapheresis Therapy-Related Complications Are Common.

Preliminary Findings from the Prospective Multicenter Surveillance, Epidemiology and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Are There Two Distinct Mechanistic Pathways That Explain the Varying Clinical Presentations, Laboratory Findings, and Outcomes of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP)?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only